• Product NameBrigatinib
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityBrigatinib is an investigational Y medicine showing promise in clinical trials as a potential treatment for certain types of lung Y.Brigatinib is a highly potent and selective investigational ALK inhibitor with mean IC50 value 100 nM in Ba/F3 cells.
• Target NameALK inhibitor; EGFR inhibitor; FLT inhibitor; IGF-1R inhibitor; ROS inhibitor
• CAS No. 1197953-54-0
• Calculated MW 584.09
• Formulation C29H39ClN7O2P
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC
  Pathways:Angiogenesis; Immunology/Inflammation; Tyrosine Kinase/Adaptors; JAK/STAT signaling
  Receptor:ALK; EGFR (C797S/del19); FLT3; IGF-1R; ROS1
  Boling pt:
  Melting pt:
  Solubility:Soluble in DMSO
  Appearance:White powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Zhang S, et al. Clin Y Res. 2016 Oct 25.;

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting